Broad Adult Indication Secured

The U.S. Food and Drug Administration (FDA) approved Mimrylo (generic name: rusfertide) by Takeda Pharmaceutical (TAK) and Protagonist Therapeutics (PTGX) on August 28, 2026, for the treatment of erythrocytosis in adult patients with polycythemia vera (PV). The label does not require prior drug use, making its commercial scope broader than market expectations that it would be limited to patients who failed hydroxyurea or Jakafi. Mimrylo is the first FDA-approved hepcidin-mimetic peptide that mimics hepcidin, a hormone regulating iron homeostasis, to limit iron supply necessary for red blood cell production. This means it can immediately enter the prescription market for the approximately 150,000 PV patients diagnosed in the U.S.

Directly Reduces Phlebotomy Burden in Phase 3

The approval is based on the randomized, double-blind Phase 3 VERIFY trial (NCT05210790), which evaluated 293 adults who required repeated phlebotomies despite standard therapy. During the 20–32 week evaluation period, 76.9% of patients in the Mimrylo group and 32.9% in the placebo group did not meet phlebotomy criteria. The clinical differentiation is its ability to maintain hematocrit below 45%, the target for thrombosis risk management, with once-weekly subcutaneous injection and compatibility with existing therapies. The most common adverse reactions were injection site reactions in 56% of patients and anemia in 16%, with platelet count monitoring also included in the label.

Competing with Standard Therapies and Pioneering Combination Market

Current treatment pillars include phlebotomy, low-dose aspirin, and cytoreductive agents such as hydroxyurea. Approved competitors include Besremi (ropeginterferon alfa-2b-njft, a type I interferon receptor modulator) by Pharnext and Jakafi (ruxolitinib, a JAK1/JAK2 inhibitor) by Incyte. The FDA approved Jakafi on December 4, 2014, for PV patients who are refractory or intolerant to hydroxyurea, and Besremi on November 12, 2021, for adult PV patients regardless of treatment history. Mimrylo targets iron utilization and erythrocytosis rather than the clonal malignancy itself, allowing it to both replace and be combined with these drugs. Takeda's data showing that 78% of patients are uncontrolled under standard therapy supports the formation of a new market focused on reducing phlebotomy.

Blockbuster Potential and Realization of Deal Value

The U.S. list price of Mimrylo is USD 4,200 per vial. Jefferies forecasts annual peak sales of up to USD 2 billion, based on the broad label and approximately 150,000 diagnosed patients. This should be viewed as a product sales opportunity combining prescribable patients and actual pricing, rather than a pure market research estimate. Protagonist received USD 300 million in upfront payment from Takeda in 2024, and will receive an additional USD 275 million tied to this approval, with potential for up to USD 875 million in total and sales royalties. Takeda secured global development and commercialization rights, and this approval marks the first substantive revenue conversion point for its late-stage pipeline, which could offset declining profits due to patent expirations.